Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.
De Souza A, Strober B, Merola J, Oliver S, Franks A. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. Journal Of Drugs In Dermatology 2012, 11: 1224-6. PMID: 23134988.Peer-Reviewed Original ResearchConceptsDiscoid lupus erythematosusDiscoid lupusLupus erythematosusCutaneous Lupus Erythematosus Disease AreaFirst open-label studyTh17-mediated immune responsesOpen-label studyChronic inflammatory disordersEffective therapeutic optionDays of treatmentAdverse eventsIL-23Psoriatic arthritisIL-12Clinical efficacyTherapeutic optionsInflammatory disordersTh1 cellsTreatment modalitiesLeukocyte productionImmune responseLabel studyEnzyme inhibitorsApremilastPilot studyA Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1
Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatology And Therapy 2012, 2: 1. PMID: 23205324, PMCID: PMC3510391, DOI: 10.1007/s13555-012-0001-y.Peer-Reviewed Original ResearchDifficult treatment scenariosPsoriatic nail diseaseSevere scalp psoriasisSystemic lupus erythematosusOptimal treatment optionsDelphi consensus approachField of psoriasisAnogenital dysplasiaConcomitant psoriasisCardiovascular morbiditySevere psoriasisOlder patientsScalp psoriasisTopical therapyLupus erythematosusPsoriasis therapyChallenging patientsHuman papillomaTreatment optionsClinical trialsConsensus panelNail diseasePsoriasisTreatment approachesClinical scenarios